Gender and Sexual Orientation Differences in Human Papillomavirus (HPV) Vaccine Uptake among Chinese Young Adults.

Edmond Choi,Janet Wong,Angel Lau,Daniel Fong

doi:10.3390/ijerph15061099

Abstract

To date, empirical studies on HPV vaccine uptake are still limited in Chinese populations and mainly conducted in female cohorts. In order to inform health services planning and health promotion programmes for HPV vaccination, this cross-sectional study aimed to report the prevalence of self-reported HPV vaccination status and to examine gender and sexual orientation differences in the uptake of HPV vaccine in Chinese college students. The overall prevalence of HPV vaccine uptake was 27.6% (n = 242), with a significantly higher prevalence in females (39.7%) than in males (4.7%). 91.4% of subjects heard about HPV vaccination, with a significantly higher prevalence in females (93.8%) than in males (86.8%). The prevalence of HPV vaccine uptake was only 2.6% for bisexual/ homosexual males and 5.0% for heterosexual males. Only 45.8% of the overall subjects knew HPV vaccination is not for females only, with a significantly higher prevalence in females (49.7%) than in males (38.6%). The low prevalence of male HPV vaccine uptake and awareness called for the need to have more male-specific HPV campaigns to promote HPV vaccination awareness and uptake in males to reduce the overall prevalence of HPV infection.

Highlights

Genital human papillomavirus (HPV) infection is the most common sexually transmitted infection (STI) in the world [1]
Empirical studies on HPV vaccine uptake are still limited in Chinese populations
In order to inform health services planning and develop health promotion programmes for HPV vaccination, this study aimed to report the prevalence of HPV vaccination and to examine gender and sexual orientation differences in the uptake of HPV vaccine among Chinese young adults

Summary

Introduction

Genital human papillomavirus (HPV) infection is the most common sexually transmitted infection (STI) in the world [1]. The health impact of HPV infection on women’s health is substantial, with 70% of cervical cancers being attributable to HPV type -16 and -18. A meta-analysis conducted in 2007 found that among Asian women with invasive cervical cancer, HPV-16 was the predominant type (52.4%), followed by HPV-18 (14.5%) [4]. Cervical cancer is the second most common cancer in women in less developed countries [5]. It was estimated that the lifetime total medical cost of HPV infection for men and women aged 15 to 24 is US$2.9 billion, which makes HPV the second most expensive STI after human immunodeficiency virus [8]

Objectives

Methods

Results

Discussion

Conclusion